Home / NHGRI Genomic Medicine Research Initiative

NHGRI Genomic Medicine Research Initiative

The National Human Genome Research Institute (NHGRI) has issued two new Funding Opportunity Announcements in support of research to utilize a patient’s own genomic information to inform clinical care and health outcomes. These Announcements represent a potential opportunity to apply an understanding of the genomics of those living with myotonic dystrophy (DM) to clinical management and treatment settings.

The stated objective of the NHGRI program is to “stimulate innovation and advance our understanding of when, where and how best to implement the use of genomic information and technologies in clinical care in all populations.” The program utilizes both R01 (PAR-18-735) and R21 (PAR-18-736) grant mechanisms. R01 applications are limited to $500,000 direct costs/year and 4 years; R21 applications to $275,000 total direct costs over 2 years. The PAR designation implies that applications will be assigned to a dedicated study section (Special Emphasis Panel or other) for review; there are no set-aside funds designated for this initiative.

Eligible activities include, but are not limited to, research studies on genome sequencing for disease diagnosis, treatment, or healthcare utilization. Interested applicants should see the Program Announcements referenced above and are strongly encouraged to discuss plans for applications with the Program Director identified in the Announcements.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.